Smoking-Related Interstitial Fibrosis (SRIF) in Patients Presenting With Diffuse Parenchymal Lung Disease
American Journal of Clinical Pathology · 01.02.2023 · 159 (2) · 146-157
DOI: 10.1093/ajcp/aqac144 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 10.12.2022. Verfasst von Susan J Vehar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Critical Care and Sleep Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. Hauptthemen laut MEDLINE: Bronchiolitis, Lung Diseases, Interstitial. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To describe the clinical, radiologic, and pathologic findings in cases where smoking-related interstitial fibrosis (SRIF) was diagnosed in surgical lung biopsy specimens from patients with clinical and imaging features of diffuse parenchymal lung disease (DPLD).
Methods
Cases were included in this study if patients had clinical and imaging evidence of DPLD and surgical lung biopsy specimens revealed SRIF. A dedicated multidisciplinary conference was held to correlate clinical, radiologic, and pathologic findings.
Results
Six cases met inclusion criteria; all six (five women/one man, aged 42-57 years, mean age 47 years) were either current smokers (five of six) or ex-smokers (one of six) and were evaluated for respiratory symptoms and abnormal pulmonary function tests, most commonly reduced forced vital capacity (n = 3) and diffusing capacity for carbon monoxide (n = 6). The most common imaging abnormalities were bilateral ground-glass opacities, which correlated with histopathologic SRIF. Follow-up of up to 10 years showed stable or improved clinical symptoms, pulmonary function tests, and radiologic findings with smoking cessation (three patients) or a decrease in smoking (three patients). No specific treatments were given, and those treated with empiric corticosteroid tapers did not show discernible responses.
Conclusions
SRIF can present as clinically meaningful diffuse parenchymal lung disease in relatively young heavy smokers, characterized by bilateral ground-glass opacities and a stable clinical course.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pulmonary Critical Care and Sleep Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
- Imaging Institute, Cleveland Clinic, Cleveland, OH, USA.
- Department of Pathology, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
- Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.
ORCID-Profile: Sanjay Mukhopadhyay
Zitieren
APA
Vehar, S. J., Yadav, R., Mukhopadhyay, S., Nathani, A., & Tolle, L. B. (2023). Smoking-Related Interstitial Fibrosis (SRIF) in Patients Presenting With Diffuse Parenchymal Lung Disease. American Journal of Clinical Pathology, 159(2), 146-157. https://doi.org/10.1093/ajcp/aqac144
Vancouver
Vehar SJ, Yadav R, Mukhopadhyay S, Nathani A, Tolle LB. Smoking-Related Interstitial Fibrosis (SRIF) in Patients Presenting With Diffuse Parenchymal Lung Disease. American Journal of Clinical Pathology. 2023;159(2):146-157. doi:10.1093/ajcp/aqac144
BibTeX
@article{Vehar2023,
author = {Vehar, Susan J and Yadav, Ruchi and Mukhopadhyay, Sanjay and Nathani, Avantika and Tolle, Leslie B},
title = {Smoking-Related Interstitial Fibrosis (SRIF) in Patients Presenting With Diffuse Parenchymal Lung Disease},
journal = {American Journal of Clinical Pathology},
year = {2023},
volume = {159},
number = {2},
pages = {146--157},
doi = {10.1093/ajcp/aqac144}
}
EUVIMED